Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Expert Rev Vaccines ; 22(1): 35-53, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36484136

RESUMO

INTRODUCTION: Vaccines prevent disease and disability; save lives and represent a good assessment of health interventions. Several systematic reviews on the efficacy and effectiveness of COVID-19 vaccines have been published, but the immunogenicity and safety of these vaccines should also be addressed. AREAS COVERED: This systemic investigation sought to explain the efficacy, immunogenicity, and safety of new vaccination technologies against SARS-CoV-2 in people over 18 years old. Original research studying the effectiveness on mRNA, protein subunit vaccines, and viral vector vaccines against SARS-CoV-2 in people over 18 years old was analyzed. Several databases (Web of Science, Scopus, MEDLINE and EMBASE) were searched between 2012 and November 2022 for English-language papers using text and MeSH terms related to SARS-CoV-2, mechanism, protein subunit vaccine, viral vector, and mRNA. The protocol was registered on PROSPERO, CRD42022341952. Study quality was assessed using the NICE methodology. We looked at a total of six original articles. All studies gathered and presented quantitative data. EXPERT OPINION: Our results suggest that new vaccinations could have more than 90% efficacy against SARS-CoV-2, regardless of the technology used. Furthermore, adverse reactions go from mild to moderate, and good immunogenicity can be observed for all vaccine types.


Assuntos
COVID-19 , Vacinas Virais , Humanos , Adolescente , Subunidades Proteicas , Vacinas contra COVID-19/efeitos adversos , SARS-CoV-2 , RNA Mensageiro , COVID-19/prevenção & controle , Vacinas de Subunidades Antigênicas/efeitos adversos , Anticorpos Antivirais , Imunogenicidade da Vacina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...